Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13D/A 0001629222 XXXXXXXX LIVE 11 Common Stock, par value $0.0001 per share 11/10/2025 false 0001326110 45256X103 ImmunityBio, Inc. 3530 John Hopkins Court San Diego CA 92121 Charles Kenworthy (310) 836-6400 Cambridge Equities, LP 450 Duley Road El Segundo CA 90245 Martin J. Waters (858) 350-2300 Wilson Sonsini Goodrich & Rosati 12235 El Camino Real San Diego CA 92130 0001629222 N Cambridge Equities, LP b AF WC OO N DE 0 261705814 0 261705814 261705814 N 26.6 PN The percentage shown in (13) is calculated based upon (x) 261,705,814 shares of the Issuer's Common Stock held by Cambridge Equities, LP ("Cambridge"), divided by (y) 984,965,179 shares of the Issuer's Common Stock issued and outstanding, as of October 30, 2025, as provided by the Issuer. 0001629186 N MP 13 Ventures, LLC b AF N DE 0 261705814 0 261705814 261705814 N 26.6 OO The percentage shown in (13) is calculated based upon (x) 261,705,814 shares of the Issuer's Common Stock held by Cambridge, divided by (y) 984,965,179 shares of the Issuer's Common Stock issued and outstanding, as of October 30, 2025, as provided by the Issuer. MP 13 Ventures, LLC ("MP 13 Ventures") may be deemed to beneficially own, and share voting power and investment power with Cambridge over, all shares of the Issuer's Common Stock beneficially owned by Cambridge. 0001675760 N NantWorks, LLC b OO N DE 0 98535253 0 98535253 98535253 N 10.0 OO The percentage shown in (13) is calculated based upon (x) the sum of (i) 9,986,920 shares of the Issuer's Common Stock held by NantWorks, LLC ("NantWorks"); (ii) 8,383,414 shares of the Issuers' Common Stock held by NantBio, Inc. ("NantBio"); (iii) 47,557,934 shares of the Issuer's Common Stock held by NantMobile, LLC ("NantMobile"); and (iv) 32,606,985 shares of the Issuer's Common Stock held by NantCancerStemCell, LLC ("NCSC") divided by (y) 984,965,179 shares of the Issuer's Common Stock issued and outstanding, as of October 30, 2025, as provided by the Issuer. NantBio, NantMobile and NCSC are majority-owned subsidiaries of NantWorks, and NantWorks shares voting and dispositive power over the shares beneficially owned by NantBio, NantMobile, and NCSC. NantWorks disclaims beneficial ownership of the shares of the Issuer's Common Stock beneficially owned by NantBio, NantMobile and NCSC, except to the extent of their pecuniary interest. 0001567221 N NantMobile, LLC b OO N DE 0 47557934 0 47557934 47557934 N 4.8 OO The percentage shown in (13) is calculated based upon (x) 47,557,934 shares of the Issuer's Common Stock beneficially owned by NantMobile divided by (y) 984,965,179 shares of the Issuer's Common Stock issued and outstanding, as of October 30, 2025, as provided by the Issuer. 0001675758 N Nant Capital, LLC b OO N DE 0 339465529 0 339465529 339464529 N 31.5 OO The percentage shown in (13) is calculated based upon (x) the sum of (i) 246,412,277 shares of the Issuer's Common Stock held by Nant Capital, LLC ("Nant Capital"); and (ii) 93,053,252 shares of the Issuers' Common Stock that Nant Capital has the right to acquire from the Issuer within 60 days of October 30, 2025 pursuant to the conversion of a promissory note divided by (y) the sum of (i) 984,965,179 shares of the Issuer's Common Stock issued and outstanding, as of October 30, 2025, as provided by the Issuer; and (ii) 93,053,252 shares of the Issuer's Common Stock that Nant Capital has the right to acquire from the Issuer with 60 days of October 30, 2025 pursuant to the conversion of a promissory note. 0001517764 N California Capital Equity, LLC b OO N DE 0 106511412 0 106511412 106511412 N 10.8 OO The percentage shown in (13) is calculated based upon (x) the sum of (i) 7,976,159 shares of the Issuer's Common Stock held by California Capital Equity, LLC ("California Capital"); (ii) 9,986,920 shars of the Issuer's Common Stock held by NantWorks; (iii) 8,383,414 shares of the Issuers' Common Stock held by NantBio; (iv) 47,557,934 shares of the Issuer's Common Stock held by NantMobile; and (v) 32,606,985 shares of the Issuer's Common Stock held by NCSC divided by (y) 984,965,179 shares of the Issuer's Common Stock issued and outstanding, as of October 30, 2025, as provided by the Issuer. NantWorks is a wholly-owned subsidiary of California Capital. NantBio, NantMobile and NCSC are majority-owned subsidiaries of NantWorks. California Capital shares voting and dispositive power over the shares beneficially owned by NantWorks, NantBio, NantMobile, and NCSC. California Capital disclaims beneficial ownership of the shares of the Issuer's Common Stock beneficially owned by NantWorks, NantBio, NantMobile and NCSC, except to the extent of their pecuniary interest. 0001189020 N Patrick Soon-Shiong b AF PF OO N X1 30670119 713301081 30670119 713301081 743971200 N 68.9 IN The percentage in (13) is calculated based upon (x) the sum of (i) 29,546,190 shares of the Issuer's Common Stock held by Dr. Patrick Soon-Shiong; (ii) 1,123,929 shares of the Issuer's Common Stock that Dr. Soon-Shiong has the right to acquire from the Issuer within 60 days of October 30, 2025 pursuant to the exercise of stock options that were exercisable as of October 30, 2025; (iii) 261,705,814 shares of the Issuer's Common Stock held by Cambridge; (iv) 7,976,159 shares of the Issuer's Common Stock held by California Capital; (v) 9,986,920 shares of the Issuer's Common Stock held by NantWorks; (vi) 246,412,277 shares of the Issuer's Common Stock held by Nant Capital; (vii) 93,053,252 shares of the Issuer's Common Stock that Nant Capital has the right to acquire from the Issuer within 60 days of October 30, 2025 pursuant to the conversion of a promissory note; (viii) 8,383,414 shares of the Issuer's Common Stock held by NantBio; (ix) 47,557,934 shares of the Issuer's Common Stock held by NantMobile; (x) 32,606,985 shares of the Issuer's Common Stock held by NCSC; and (xi) 5,618,326 shares of the Issuer's Common Stock held by the Chan Soon-Shiong Family Foundation divided by (y) the sum of (i) 984,965,179 shares of the Issuer's Common Stock issued and outstanding, as of October 30, 2025, as provided by the Issuer; (ii) 1,123,929 shares of the Issuer's Common Stock that Dr. Soon-Shiong has the right to acquire from the Issuer within 60 days of October 30, 2025 pursuant to the exercise of stock options that were exercisable as of October 30, 2025; and (iii) 93,053,252 shares of the Issuer's Common Stock that Nant Capital has the right to acquire from the Issuer within 60 days of October 30, 2025, pursuant to the conversion of a promissory note. Dr. Soon-Shiong may be deemed to beneficially own, and share voting power and investment power over, all shares of the Issuer's Common Stock beneficially owned by Cambridge, California Capital, NantWorks, NantBio, NantMobile, NCSC, Nant Capital, and the Chan Soon-Shiong Family Foundation. Dr. Soon-Shiong disclaims beneficial ownership of the shares of the Issuer's Common Stock beneficially owned by Cambridge, California Capital, NantWorks, NantBio, NantMobile, NCSC, Nant Capital, and the Chan Soon-Shiong Family Foundation except to the extent of his pecuniary interest. Common Stock, par value $0.0001 per share ImmunityBio, Inc. 3530 John Hopkins Court San Diego CA 92121 In the case of NantMobile, LLC, their beneficial ownership percentage ceased to be more than five percent of the Issuer's Common Stock as of October 30, 2025. The following documents are filed as exhibits: Exhibit 99.1 Joint Filing Agreement, dated as of September 21, 2023, by and among Cambridge Equities, LP, MP 13 Ventures, LLC, NantWorks, LLC, NantMobile, LLC, Nant Capital, LLC, California Capital Equity, LLC, and Patrick Soon-Shiong (incorporated by reference to Exhibit 99.1 to the Sch 13D/A (Amendment No. 9) filed with the SEC by the Reporting Persons on September 21, 2023). Exhibit 99.2 Nominating Agreement by and between the Issuer and Cambridge Equities, LP, dated June 18, 2015 (incorporated by reference to Exhibit 4.1 to the Issuer's Registration Statement on Form S-1 (File No. 333-205124) filed with the SEC on June 19, 2015). Registration Rights Agreement by and between the Issuer and Cambridge Equities, LP, dated December 23, 2014 (incorporated by reference to Exhibit 4.3 to the Issuer's Registration Statement on Form S-1 (File No. 333-205124) filed with the SEC on June 19, 2015). Cambridge Equities, LP /s/ Charles Kenworthy Charles Kenworthy, Manager of MP 13 Ventures, LLC, the General Partner of Cambridge Equities, LP 11/10/2025 MP 13 Ventures, LLC /s/ Charles Kenworthy Charles Kenworthy, Manager 11/10/2025 NantWorks, LLC /s/ Robert Morse Robert Morse, CFO of NantWorks, LLC 11/10/2025 NantMobile, LLC /s/ Robert Morse Robert Morse, CFO of NantMobile, LLC 11/10/2025 Nant Capital, LLC /s/ Charles Kenworthy Charles Kenworthy, Manager of Nant Capital, LLC 11/10/2025 California Capital Equity, LLC /s/ Charles Kenworthy Charles Kenworthy, Manager of California Capital Equity, LLC 11/10/2025 Patrick Soon-Shiong /s/ Patrick Soon-Shiong Patrick Soon-Shiong 11/10/2025